sarpogrelate has been researched along with Intermittent Claudication in 2 studies
sarpogrelate: structure given in first source
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent claudication." | 9.12 | Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study. ( Arita, K; Jawien, A; Mátyás, L; Norgren, L; Riegerd, H, 2006) |
| "Sarpogrelate has a therapeutic effect on patients with atherosclerotic obliterans." | 6.78 | Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( Liu, J; Liu, P; Qian, S; Ren, S; Wang, W, 2013) |
| "This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent claudication." | 5.12 | Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study. ( Arita, K; Jawien, A; Mátyás, L; Norgren, L; Riegerd, H, 2006) |
| "Sarpogrelate has a therapeutic effect on patients with atherosclerotic obliterans." | 2.78 | Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( Liu, J; Liu, P; Qian, S; Ren, S; Wang, W, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ren, S | 1 |
| Qian, S | 1 |
| Wang, W | 1 |
| Liu, J | 1 |
| Liu, P | 1 |
| Norgren, L | 1 |
| Jawien, A | 1 |
| Mátyás, L | 1 |
| Riegerd, H | 1 |
| Arita, K | 1 |
2 trials available for sarpogrelate and Intermittent Claudication
| Article | Year |
|---|---|
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans.
Topics: Aged; Ankle Brachial Index; Arteriosclerosis Obliterans; Cardiovascular Agents; Chi-Square Distribut | 2013 |
Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.
Topics: Adult; Aged; Double-Blind Method; Europe; Exercise Test; Female; Humans; Intermittent Claudication; | 2006 |